Precipio Launches ICE COLD-PCR™ Liquid Biopsy Kit for Pancreatic Cancer
Precipio, Inc. (PRPO)
US:NASDAQ Investor Relations:
precipiodx.com/investors.html
Company Research
Source: GlobeNewswire
Ultra-sensitive enrichment kit enables development of low cost detection tests, allowing optimized patient treatment NEW HAVEN, Conn., May 17, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced the launch of two additional ICEme™ kits using its proprietary ICE-COLD PCR™ liquid biopsy technology. The new RUO kits enable the detection of mutations in KRAS Exons 2 & 3, which include important predictive and prognostic biomarkers, and are available on both qPCR and Sanger molecular diagnostic platforms. The Challenges of Pancreatic Cancer Over 55,000 patients are diagnosed with pancreatic cancer each year in the US; approximately 80% will die each year. The 5-year survival rate for stage I pancreatic cancer is ~14%, a number that drops to 3% for stage III patients, and 1% for stage IV patients1. Only 7% of patients are diagnosed in early stages, when the disease is still localized2. Treatment for pancreatic cancer includes surgery, r
Show less
Read more
Impact Snapshot
Event Time:
PRPO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRPO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRPO alerts
High impacting Precipio, Inc. news events
Weekly update
A roundup of the hottest topics
PRPO
News
- Precipio Announces Year end 2023 Shareholder Update CallGlobeNewswire
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY [Yahoo! Finance]Yahoo! Finance
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYGlobeNewswire
- Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for CancerGlobeNewswire
PRPO
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- PRPO's page on the SEC website